Cuyàs, E., Gumuzio, J., Verdura, S., Brunet, J., Bosch-Barrera, J., Martin-Castillo, B., . . . Menendez, J. (2020). The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: A potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes.
Chicago Style CitationCuyàs, E., et al. The LSD1 Inhibitor Iadademstat (ORY-1001) Targets SOX2-driven Breast Cancer Stem Cells: A Potential Epigenetic Therapy in Luminal-B and HER2-positive Breast Cancer Subtypes. 2020.
MLA CitationCuyàs, E., et al. The LSD1 Inhibitor Iadademstat (ORY-1001) Targets SOX2-driven Breast Cancer Stem Cells: A Potential Epigenetic Therapy in Luminal-B and HER2-positive Breast Cancer Subtypes. 2020.
Warning: These citations may not always be 100% accurate.